MiR-93 is related to poor prognosis in pancreatic cancer and promotes tumor progression by targeting microtubule dynamics
Open Access
- 4 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogenesis
- Vol. 9 (5), 1-14
- https://doi.org/10.1038/s41389-020-0227-y
Abstract
Biomarkers and effective therapeutic agents to improve the dismal prognosis of pancreatic ductal adenocarcinoma (PDAC) are urgently required. We aimed to analyze the prognostic value and mechanistic action of miR-93 in PDAC. Correlation of miR-93 tumor levels from 83 PDAC patients and overall survival (OS) was analyzed by Kaplan–Meier. MiR-93 depletion in PANC-1 and MIA PaCa-2 cells was achieved by CRISPR/Cas9 and miR-93 overexpression in HPDE cells by retroviral transduction. Cell proliferation, migration and invasion, cell cycle analysis, and in vivo tumor xenografts in nude mice were assessed. Proteomic analysis by mass spectrometry and western-blot was also performed. Finally, miR-93 direct binding to candidate mRNA targets was evaluated by luciferase reporter assays. High miR-93 tumor levels are significantly correlated with a worst prognosis in PDAC patients. MiR-93 abolition altered pancreatic cancer cells phenotype inducing a significant increase in cell size and a significant decrease in cell invasion and proliferation accompanied by a G2/M arrest. In vivo, lack of miR-93 significantly impaired xenograft tumor growth. Conversely, miR-93 overexpression induced a pro-tumorigenic behavior by significantly increasing cell proliferation, migration, and invasion. Proteomic analysis unveiled a large group of deregulated proteins, mainly related to G2/M phase, microtubule dynamics, and cytoskeletal remodeling. CRMP2, MAPRE1, and YES1 were confirmed as direct targets of miR-93. MiR-93 exerts oncogenic functions by targeting multiple genes involved in microtubule dynamics at different levels, thus affecting the normal cell division rate. MiR-93 or its direct targets (CRMP2, MAPRE1, or YES1) are new potential therapeutic targets for PDAC.Keywords
Funding Information
- Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI17/01003)
This publication has 44 references indexed in Scilit:
- Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cellsDrug Design, Development and Therapy, 2013
- 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testingBMC Cancer, 2013
- miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic CystsClinical Cancer Research, 2012
- Cancer microRNAs: From subtype profiling to predictors of response to therapyTrends in Molecular Medicine, 2011
- Collapsin Response Mediator Protein-2 (Crmp2) Regulates Trafficking by Linking Endocytic Regulatory Proteins to Dynein MotorsOnline Journal of Public Health Informatics, 2010
- Phosphorylation of Collapsin Response Mediator Protein 2 on Tyr-479 Regulates CXCL12-induced T Lymphocyte MigrationOnline Journal of Public Health Informatics, 2009
- Roles for MicroRNAs, miR-93 and miR-130b, and Tumor Protein 53–Induced Nuclear Protein 1 Tumor Suppressor in Cell Growth Dysregulation by Human T-Cell Lymphotrophic Virus 1Cancer Research, 2008
- Molecular targeted therapies for pancreatic cancerThe American Journal of Surgery, 2008
- Cdk1 is sufficient to drive the mammalian cell cycleNature, 2007
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006